Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019.
作者信息
Mombrun Martin, Valette Xavier
机构信息
Department of Medical Intensive Care, CHU de Caen Normandie, Caen, France.
Department of Medical Intensive Care, CHU de Caen Normandie, Caen, France.
出版信息
Chest. 2021 May;159(5):2115-2116. doi: 10.1016/j.chest.2020.11.069.
Abstract
摘要
相似文献
1
Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019.对2019冠状病毒病住院患者使用托珠单抗提出质疑。
Chest. 2021 May;159(5):2115-2116. doi: 10.1016/j.chest.2020.11.069.
2
Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series.白细胞介素-6拮抗剂托珠单抗治疗重症冠状病毒病2019细胞因子释放综合征患者：病例系列
J Cardiothorac Vasc Anesth. 2021 Jul;35(7):2237-2239. doi: 10.1053/j.jvca.2020.10.040. Epub 2020 Oct 24.
3
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
4
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
5
Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic.快速分析当地数据，以便在 COVID-19 大流行早期为托珠单抗的超适应证使用提供信息。
Healthc (Amst). 2021 Dec;9(4):100581. doi: 10.1016/j.hjdsi.2021.100581. Epub 2021 Sep 9.
6
Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.托珠单抗治疗中重度 COVID-19 患者：一项回顾性队列研究。
J Clin Pharm Ther. 2021 Apr;46(2):440-446. doi: 10.1111/jcpt.13303. Epub 2020 Oct 24.
7
Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS-CoV-2 infection in Taiwan.托珠单抗可缓解台湾地区严重SARS-CoV-2感染伴急性呼吸窘迫综合征的细胞因子风暴。
Intern Med J. 2021 Sep;51(9):1543-1544. doi: 10.1111/imj.15335.
8
Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.接受糖皮质激素联合或不联合托珠单抗治疗COVID-19相关过度炎症的患者对SARS-CoV-2的抗体反应。
Ann Rheum Dis. 2021 Oct;80(10):1362-1363. doi: 10.1136/annrheumdis-2021-220040. Epub 2021 May 6.
9
Feasibility of tocilizumab in ICU patients with COVID-19.托珠单抗用于新冠肺炎重症监护病房患者的可行性。
J Med Virol. 2021 Jan;93(1):46-47. doi: 10.1002/jmv.26110. Epub 2020 Aug 13.
10
Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.托珠单抗治疗 COVID-19 诱导的细胞因子风暴和急性呼吸窘迫综合征：来自宾夕法尼亚州西部农村一级创伤中心的病例系列。
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211019557. doi: 10.1177/23247096211019557.
本文引用的文献
1
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
2
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
3
A living WHO guideline on drugs for covid-19.关于新冠病毒药物的世界卫生组织实用指南。
BMJ. 2020 Sep 4;370:m3379. doi: 10.1136/bmj.m3379.
4
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.托珠单抗治疗 COVID-19 住院患者细胞因子释放综合征：生存和临床结局。
Chest. 2020 Oct;158(4):1397-1408. doi: 10.1016/j.chest.2020.06.006. Epub 2020 Jun 15.
5
Current concepts in the diagnosis and management of cytokine release syndrome.细胞因子释放综合征的诊断和治疗的当前概念。
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
Zotero 插件